

MYRIAD GENETICS INC  
Form 8-K  
April 01, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 1, 2014**

**MYRIAD GENETICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**0-26642**  
**(Commission**

**File Number)**  
**320 Wakara Way**

**87-0494517**  
**(IRS Employer**

**Identification No.)**

**Salt Lake City, Utah 84108**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (801) 584-3600**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 7.01 Regulation FD Disclosure.**

On April 1, 2014, the Centers for Medicare & Medicaid Services (CMS) provided new, updated pricing for the sequencing of the BRCA1 and BRCA2 genes. The new pricing resulted in a total reimbursement amount for Myriad's integrated BRCA<sup>Analysis</sup>® of \$2,767. Below is a summary of the change in pricing for the relevant codes:

Description and CPT Code	Previous FY14 CMS Pricing	New FY14 CMS Pricing	Percent Change
BRCA 1&2 seq & com dup/del (81211) <b>BRCA<sup>Analysis</sup></b>	\$1,438	\$2,184	52%
BRCA 1&2 uncom dup/del var (81213) <b>BART®</b>	\$583	\$583	No Change
<b>Integrated BRCA<sup>Analysis</sup></b>	\$2,021	\$2,767	37%

The new reimbursement amounts will take effect for tests ordered on or after April 1, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: April 1, 2014

By: /s/ Peter D. Meldrum  
Peter D. Meldrum  
President and Chief Executive Officer

Page 3 of 3 pages